ClinicalTrials.gg
Enrolling by invitationNCT06800846Updated Jun 4, 2025

Comparative Analgesic Effect After Total Knee Arthroplasty Between Intraosseous and Peri-articular Injection

A Phase 4 interventional study of Intraosseous Morphine and Periarticular Injection in Pain Postoperative, Total Knee Anthroplasty and Functional Outcomes, sponsored by Thammasat University Hospital. Enrolling by invitation at 1 site in Thailand. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-06-04.

Sponsored by Thammasat University Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 5 months ago, but the record still lists the study as enrolling by invitation.
  • Registered 4 months after the study started (first participant enrolled Sep 2024, registered Jan 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Pain, Postoperative with a site in Thailand — 5 open to participants now, 9 under way, 1 of them phase 3. Pain, Postoperative · Thailand.

Planned enrollment
26th of 63
90 · median 80
Started
2024
with 4 others
Phase 4
25 of 69
2 open now
Registered
64th of 69
by date
Lead sponsor
3 of 69
Thammasat University Hospital

Among the 69 studies in Pain, Postoperative with a site in Thailand, this one is the 26th largest by planned enrollment of the 63 interventional ones that give a count, is one of 5 that started in 2024, is one of 25 in phase 4, and was the 64th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

5 of the 69 studies in Pain, Postoperative with a site in Thailand are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Thailand have not opened yet or have stopped. Only those recruiting at a site in Thailand →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Pain, Postoperative with a site in Thailand, or all of them as a file.
02

Study summary

The goal of this RCT is to compare analgesic effect after total knee arthroplasty between intraosseous multimodal analgesic agent injection versus periarticular injection. The main question[s] it aims to answer are: Does Intraosseous multimodal analgesic cocktail injection have more post-operative analgesic effect than Peri-articular injection in patients who have done TKA (P)? Participants will randomized to intraosseous injection group or peri-articular injection group and will record the 100-mm VAS pain scores for 2 weeks after TKA. Researchers will compare to peri-articular injection group to see pain and functional outcomes after TKA.

Read the detailed description

Intra-operatively, you will be randomly assigned to receive intraosseous multimodal analgesic agent injection or peri-articular multimodal analgesic agent injection along with other standard medications. In the intraosseous injection group: Participants received combinations of 0.5% bupivacaine 100 mg + 0.1% adrenaline 0.6 mg + Morphine 5mg + Ketorolac 30 mg (totally 22 ml) which divided by 12 ml inject into intramedullary canal before bone plug impaction to close the canal and 10 ml inject into metaphysis of tibia before cementation and implantation. In the peri-articualr injection group: Participants received combinations of the same drug and mix with normal saline solution for totally 75 ml which divided by 25 ml inject into medial gutter and 25 ml inject into lateral gutter before cementation and implantation. And the last 25 ml of multimodal analgesic drugs were injected into quadriceps.

03

Conditions studied

  • Pain Postoperative
  • Total Knee Anthroplasty
  • Functional Outcomes

Browse trials for

Keywords

  • peri-articular injection
  • intraosseous injection
  • multimodal analgesia cocktail
  • TKA
  • pain postoperative
  • functional outcomes
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 50 - 80 yrs of age : 1-3 Unilateral TKA

Exclusion criteria

Exclusion Criteria:

  • Secondary OA knee Previous knee surgery Can't undertaken spinal block and adductor canal block Renal insuf. (Crcl \< 30 ml/min) History of convulsive disorder Abnormal liver function > 35 Kg/M2 Allergy to study drugs History of coronary disease \< 10 (g/dl) Can't understand 100mm-VAS assessment Refuse to recruit in the study, or refuse follow up Using opioid in 5 days before surgery Unstable vital sign History current VTE Using anti- or anti-coagulation medicine Severe deformity
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Intraosseous multimodal analgesia injection

    Participants received combinations of 0.5% bupivacaine 100 mg + 0.1% adrenaline 0.6 mg + Morphine 5mg + Ketorolac 30 mg (totally 22 ml) which divided by 12 ml inject into intramedullary canal before bone plug impaction to close the canal and 10 ml inject into metaphysis of tibia before cementation and implantation

    Procedure: Intraosseous Morphine

  • Active comparator
    peri-articular multimodal analgesia injection

    Participants received combinations of 0.5% bupivacaine 100 mg + 0.1% adrenaline 0.6 mg + Morphine 5mg + Ketorolac 30 mg and mix with normal saline solution for totally 75 ml which divided by 25 ml inject into medial gutter and 25 ml inject into lateral gutter before cementation and implantation. And the last 25 ml of multimodal analgesic drugs were injected into quadriceps.

    Procedure: Periarticular Injection

Interventions

  • ProcedureIntraosseous Morphine

    Participants received combinations of 0.5% bupivacaine 100 mg + 0.1% adrenaline 0.6 mg + Morphine 5mg + Ketorolac 30 mg (totally 22 ml) which divided by 12 ml inject into intramedullary canal before bone plug impaction to close the canal and 10 ml inject into metaphysis of tibia before cementation and implantation

    Also known as: intraosseous injection

  • ProcedurePeriarticular Injection

    Participants received combinations of 0.5% bupivacaine 100 mg + 0.1% adrenaline 0.6 mg + Morphine 5mg + Ketorolac 30 mg and mix with normal saline solution for totally 75 ml which divided by 25 ml inject into medial gutter and 25 ml inject into lateral gutter before cementation and implantation. And the last 25 ml of multimodal analgesic drugs were injected into quadriceps.

    Also known as: peri-articular injection

06

What researchers measure

Primary outcomes

  1. pain scores

    Visual analog scale at rest and motion (0-100 points, 0 mean best, 100 mean worst)

    Time frame: at 4, 6 hours and every 6 hours after surgery for 2 days, then daily for 2 weeks after surgery.

Secondary outcomes

  1. Morphine consumption

    Morphine consumption in hospital 48 hours before discharge and MST as home medication for 2 weeks (MME)

    Time frame: 2 weeks

  2. number of vomit events

    number of vomit events

    Time frame: at first 48 hours before discharge and after discharge for 2 weeks after surgery

  3. Number of other Events of Morphine side effect

    Itching, rash, constipation, difficult urination, respiratory, etc.

    Time frame: 2 weeks after surgery

  4. ROM

    ROM (degree)

    Time frame: before surgery and 24, 48hours and 2 weeks after surgery

  5. Timed up and go test

    start with standing and then walk for 3 meters, then turn back to seat for 3 meters, then sit (report in seconds)

    Time frame: at 48 hours and 2 weeks after surgery

  6. Length of stays in hospital

    Number of hours the patient stays for surgery

    Time frame: up to 72 hours

  7. Time to walk

    hours after surgery of patients at first start walking to the toilet

    Time frame: up to 48 hours

  8. Operative time

    duration from start incision to wound closure in TKA procedure (minutes)

    Time frame: up to 2 hours

  9. Number of other complication

    clinical VTE, wound and skin complication, superficial and deep infection

    Time frame: 2 weeks

07

Study locations

1 site
08

References and documents

Publications

  • McNamara CA, Laurita J, Lambert BS, Sullivan TC, Clyburn TA, Incavo SJ, Park KJ. A multimodal intraosseous infusion of morphine and ketorolac decreases early postoperative pain and opioid consumption following total knee arthroplasty. Knee. 2023 Aug;43:129-135. doi: 10.1016/j.knee.2023.06.002. Epub 2023 Jul 1. PubMed 37399631 ↗
  • Lamplot JD, Wagner ER, Manning DW. Multimodal pain management in total knee arthroplasty: a prospective randomized controlled trial. J Arthroplasty. 2014 Feb;29(2):329-34. doi: 10.1016/j.arth.2013.06.005. Epub 2013 Jul 11. PubMed 23850410 ↗
  • Brozovich AA, Incavo SJ, Lambert BS, Sullivan TC, Wininger AE, Clyburn TA, Taraballi F, Park KJ. Intraosseous Morphine Decreases Postoperative Pain and Pain Medication Use in Total Knee Arthroplasty: A Double-Blind, Randomized Controlled Trial. J Arthroplasty. 2022 Jun;37(6S):S139-S146. doi: 10.1016/j.arth.2021.10.009. Epub 2022 Mar 7. PubMed 35272897 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for May 2025, 8 months after the start.

Of 535 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's planned 8 months is below that.

Counting every sponsor, half of 545 studies reached it within 16 months; a quarter within 8 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2025
First posted
Jan 30, 2025
StartActual
Sep 1, 2024
Primary completionEst.
May 31, 2025
CompletionEst.
Jun 30, 2025
Last update
Jun 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06800846
Lead sponsor
Thammasat University Hospital
Responsible party
Yot Tanariyakul (Comparative analgesic effect after total knee arthroplasty between intraosseous multimodal analgesic agent injection versus periarticular injection - A Randomized Control Trial, Thammasat University Hospital) — Principal investigator
First posted
Jan 30, 2025
Start date
Sep 1, 2024
Primary completion
May 31, 2025 (estimated)
Completion
Jun 30, 2025 (estimated)
Last update
Jun 4, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion